UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(AMENDMENT NO. 1)*
PROTALIX BIOTHERAPEUTICS, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $.001 PER SHARE
(Title of Class of Securities)
74365A101
(CUSIP Number)
BARAK LUCHTENSTEIN, ADV.
CBLS LAW OFFICES
5 AZRIELI CENTER, SQUARE TOWER, 35TH FLOOR
132 MENACHEM BEGIN ROAD
TEL AVIV 06725 ISRAEL
+972-3-718-8700
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
SEPTEMBER 24, 2009
(Date of Event Which Requires Reporting of this Statement)
If the reporting person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is
reporting this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check
the following box. [_]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the Schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial reporting on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
--------------------------------------------------------------------------------
CUSIP No.: 74365A101
--------------------------------------------------------------------------------
1 Name or Reporting Person
Marathon Investments Ltd.
--------------------------------------------------------------------------------
2 Check the Appropriate Box If a Member of a Group (See Instructions)
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 Source of Funds (See Instructions)
WC
--------------------------------------------------------------------------------
5 Check If Disclosure of Legal Proceedings is Required Pursuant to Item 2(d)
or 2(e) [_]
--------------------------------------------------------------------------------
6 Citizenship or Place of Organization:
Israel
--------------------------------------------------------------------------------
7 Sole Voting Power
4,777,304
Number of -------------------------------------------------------------
Shares 8 Shared Voting Power
Beneficially None
Owned by -------------------------------------------------------------
Each 9 Sole Dispositive Power
Reporting 4,777,304
Person with -------------------------------------------------------------
10 Shared Dispositive Power
None
--------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person:
4,777,304
--------------------------------------------------------------------------------
12 Check If the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) [_]
--------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11)
6.24%
--------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)
IV
--------------------------------------------------------------------------------
Page 2 of 7
This Amendment No. 1 amends and supplements the Statement on Schedule 13D (as
amended from time to time, the "Statement") in respect of the common stock, par
value $0.001 per share (the "Common Stock"), of Protalix BioTherapeutics Inc.
(the "Issuer"), initially filed with the Securities and Exchange Commission
("SEC") by the Reporting Person (as defined in the Statement) on October 29,
2008.
This Amendment No. 1 is filed in view of a material decrease in the percentage
of Common Stock beneficially owned by Marathon (as defined below) following
certain sales of Common Stock made by Marathon, and in view of Mr. Sharon
Toussia-Cohen's resignation from the Board of Directors of the Issuer on May 10,
2009.
Unless otherwise defined in this Amendment No. 1, capitalized terms have the
meanings given to them in the Statement.
The following amends and supplements Items 2, 4, 5 and 7 of the Statement.
ITEM 2. IDENTITY AND BACKGROUND.
Item 2 of the Statement is hereby amended and restated in its entirety as
follows:
(a) This Schedule 13D is being filed on behalf of Marathon Investments
Ltd., an investment company organized under the laws of the State of Israel
("Marathon"). Marathon is referred to herein from time to time as a "Reporting
Person".
(b) The address of the principal offices of Marathon is 1 Azrieli Center,
Round Tower, 19th Floor, 132 Menachem Begin Road, Tel Aviv 67021 Israel.
(c) Marathon is an investment company organized under the laws of the State
of Israel and is publicly-traded on the Tel Aviv Stock Exchange. Marathon is
engaged in the business of acquiring, holding and disposing of interests in
various companies for investment purposes. Until December 2004, Marathon
invested its funds mostly in venture capital investments. On December 2004,
Marathon's board of directors resolved to focus Marathon's investments on
yielding industrial corporations. Marathon's investments in the Issuer were made
prior to said resolution.
(d) During the past five years, the Reporting Person has not been convicted
in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) The Reporting Persons is nor, during the last five years, was subject
to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state securities laws
as a result of a civil proceeding before a judicial or administrative body of
competent jurisdiction nor has any such judicial or administrative body found
that the Reporting Person was in violation of such laws.
(f) Marathon is a corporation organized under the laws of the State of
Israel.
Set forth on Exhibit A to this Statement, and incorporated herein by reference,
is the name, residence or business address, present principal occupation or
employment, and citizenship, of each executive officer and director of Marathon.
Page 3 of 7
To the best of the Reporting Person's knowledge none of Marathon's directors or
executive officers during the last five years, (a) has been convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors) or
(b) has been a party to a civil proceeding before a judicial or administrative
body of competent jurisdiction and as a result of such proceeding was or is
subject to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state securities laws
or finding any violation with respect to such laws.
ITEM 4. PURPOSE OF TRANSACTION.
Item 4 of the Statement is hereby amended and restated in its entirety as
follows:
The purpose of the acquisition of the Common Stock by the Reporting Person is
general investment purposes. In addition, the Reporting Person may, from time to
time, depending on prevailing market, economic and other conditions, sell its
shares of Common Stock of the Issuer or acquire additional shares of Common
Stock or other securities of the Issuer or engage in discussions with the Issuer
concerning further acquisitions of shares of the Common Stock or other
securities of the Issuer or further investments in the Issuer. The Reporting
Person intends to review its investment in the Issuer on a continuing basis and,
depending upon the price and availability of shares of Common Stock, subsequent
developments affecting the Issuer, the Issuer's business and prospects, other
investment and business opportunities available to the Reporting Person, general
stock market and economic conditions, tax considerations and other factors
considered relevant, may decide at any time to increase or to decrease the size
of its investment in the Issuer.
Except as set forth in this Schedule 13D, as amended, the Reporting Person has
made no proposals, and have entered into no agreements, which would be related
to or would result in any of the events or matters described in Item 4 of
Schedule 13D, as amended.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
Item 5 of the Statement is hereby amended and restated in its entirety as
follows:
The Issuer has advised the Reporting Person that there were 76,614,924 Common
Stock outstanding on September 15, 2009. The percentage of Common Stock
outstanding owned by the Reporting Person set forth in this Statement is based
on this number.
(a) As of September 24, 2009, Marathon is the record holder of 4,777,304 shares
of Common Stock, representing approximately 6.24% of the issued and outstanding
shares of Common Stock. Marathon's investment and voting decisions are made
collectively by its Board of Directors.
(b) Marathon has sole power to vote or direct the vote and sole power to dispose
or direct the disposition of 4,777,304 shares of Common Stock.
(c) The Reporting Person or, to the Reporting Person's knowledge, any of its
executive officers and directors named in Exhibit 1 to this Statement, has not
engaged in any transaction involving any of the securities of the Issuer during
the sixty days prior to the date of this report, except as set forth below.
Page 4 of 7
Marathon made the following sales of shares of Common Stock, all of which were
made in open market transactions on the NASDAQ:
AMOUNT OF SHARES OF PRICE PER SHARE
DATE COMMON STOCK (US$)
------- ------- -------
August 13, 2009 3,427 6.2290
August 17, 2009 236,816 6.3285
August 18, 2009 1,200 6.1083
August 18, 2009 100,000 6.1000
August 18, 2009 11,300 6.4238
August 20, 2009 50,000 6.1000
August 25, 2009 55,000 6.4686
September 1, 2009 70,000 6.7669
September 2, 2009 52,600 7.1433
September 3, 2009 70,000 7.2829
September 4, 2009 39,532 7.3318
September 8, 2009 141,012 7.6023
September 9, 2009 69,300 7.5878
September 10, 2009 2,100 7.5977
September 14, 2009 123,576 7.4618
September 21, 2009 17,400 7.3254
September 22, 2009 20,814 7.5794
September 23, 2009 115,000 8.0147
(d) Not applicable.
(e) Mr. Sharon Toussia-Cohen ceased to be a Reporting Person following his
resignation from the Board of Directors of the Issuer on May 10, 2009.
Page 5 of 7
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief, we certify
that the information set forth in this Statement is true, complete and correct.
Dated: September 24, 2009
MARATHON INVESTMENTS LTD.
By: /s/ Sharon Toussia-Cohen
----------------------------
Sharon Toussia-Cohen,
Chief Executive Officer
Page 6 of 7
EXHIBIT A
EXECUTIVE OFFICERS AND DIRECTORS OF REPORTING PERSONS
CITIZENSHIP /
JURISDICTION OF PRINCIPAL OCCUPATION
NAME ORGANIZATION OR EMPLOYMENT
---------------------- ---------------------- ----------------------
Rafael Silman Israel Active Chairman of the Board of
Directors in Marathon.
Sharon Toussia-Cohen Israel Chief Executive Officer and
Member of the Board of
Directors in Marathon.
Itzhak Rozen Israel Member of the Board of
Directors in Marathon;
Engineer.
Yochanan Korman Israel Member of the Board of
Directors in Marathon;
Financial consultant.
Tamar Cohen Israel Member of the Board of
Directors in Marathon;
Business and organizational
consultant.
Ronen Petel Israel Member of the Board of
Directors in Marathon;
CFO of a convention center.
Avraham Naveh Israel Member of the Board of
Directors in Marathon;
CFO in an industrial group.
---------------------
Mssrs. Silman and Toussia-Cohen are executive officers and employees of Marathon
Investments Ltd., located at 1 Azrieli Center, Round Tower, 19th Floor, 132
Menachem Begin Road, Tel Aviv 06721 Israel. Except for Mssrs. Silman and
Toussia-Cohen there are no other executive officers in Marathon.
Page 7 of 7